Jui Vyas

Dr. Jui Vyas

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
FAF Ali
F Ali
JVJui Vyas
Jui Vyas
AFA Finlay
A Finlay
Atopic dermatitis is the most prevalent chronic inflammatory skin condition globally. The burden of ...

25 April 2008 in Allergy
Verified
Journal Article
Closed access
PDF file
AWA. Wollenberg
A. Wollenberg
SRS. Reitamo
S. Reitamo
FAF. Atzori
F. Atzori
MLM. Lahfa
M. Lahfa
TRT. Ruzicka
T. Ruzicka
FGfor the European Tacrolimus Ointment Study Group
for the European Tacrolimus Ointment Study Group

2 May 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
JVJui Vyas
Jui Vyas
NMNina Muirhead
Nina Muirhead
RSRavinder Singh
Ravinder Singh
RERachel Ephgrave
Rachel Ephgrave
AFAndrew Finlay
Andrew Finlay
Objectives The aim of this study was to assess the impact of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) on the quality of life (QoL) of people with ME/CFS and their relative or partner (family member). Design A patient-partner, multinational, subject-initiated, cross-sectional online survey. Setting International survey using ME/CFS charities, support groups and social media. Participants Participants were self-selected with recruitment via social media. Inclusion criteria were aged 18 years or over and reported diagnosis of ME/CFS by health professional. 1418 people with ME/CFS and their 1418 family members from 30 countries participated in the survey. Participants with ME/CFS had a mean age of 45.8 years (range 18–81) and were predominantly women (1214 (85.6%) of 1418). Family members had a mean age of 51.9 years (range 18–87) and were predominantly men (women: 504 (35.5%) of 1418). 991 (70%) family members were partners of the people with ME/CFS. Interventions EuroQoL-5 Dimension (EQ-5D-3L), completed by people with ME/CFS, and Family Reported Outcome Measure (FROM-16) questionnaire, completed by family members. Results The mean overall health status on a Visual Analogue Scale for people with ME/CFS was 33.8 (0=worst, 100=best). People with ME/CFS were most affected by ability to perform usual activities, pain, mobility, self-care and least impacted by anxiety. For family members, the overall mean FROM-16 score was 17.9 (0=no impact, 32=worst impact), demonstrating a major impact on QoL. Impact on QoL was significantly correlated between the person with ME/CFS and their family member (p<0.0001). Family members were most impacted emotionally by worry, frustration and sadness and personally by family activities, holidays, sex life and finances. Conclusions To the best of our knowledge, this is the largest study on the impact of the QoL of persons with ME/CFS and their family members. While open participation surveys are limited by selection bias, this research has revealed a significant worldwide burden of ME/CFS on the QoL of people with ME/CFS and their family members.

12 October 2016 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
FAF.M. Ali
F.M. Ali
ACA.C. Cueva
A.C. Cueva
JVJui Vyas
Jui Vyas
AAAusama Atwan
Ausama Atwan
SSSam Salek
Sam Salek
VPV. Piguet
V. Piguet

15 October 2012 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
NMNeilia‐Kay McGill
Neilia‐Kay McGill
JVJui Vyas
Jui Vyas
TSTakatoshi Shimauchi
Takatoshi Shimauchi
YTYoshiki Tokura
Yoshiki Tokura
VPVincent Piguet
Vincent Piguet

13 September 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
JVJui Vyas
Jui Vyas
JJJ. R. Johns
J. R. Johns
YAY. Abdelrazik
Y. Abdelrazik
FAF. M. Ali
F. M. Ali
JIJ. R. Ingram
J. R. Ingram
AFAndrew Finlay
Andrew Finlay
Background: The validation of psychometric measures requires use of other established and standardized validated measures. The Dermatology Life Quality Index (DLQI) is the most widely used tool to measure the burden of skin diseases and assess effectiveness of interventions based on patients' perspective.Objectives: The objective of this study was to systematically analyse peer‐reviewed publications describing use of the DLQI in validation of other patient‐reported outcome (PRO) and quality‐of‐life (QoL) measures.Methods: Seven databases were searched for papers published between January 1994 and December 2022 for articles containing data using DLQI in the validation of other PRO/QoL measures. The methodology followed PRISMA guidelines. The protocol was prospectively registered on PROSPERO.Results: Of 1717 screened publications, 122 articles including 30,727 patients from 34 different countries with 41 diseases met the inclusion criteria. The DLQI was used in validation of 101 measures: 80 dermatology‐specific QoL measures, mostly disease‐specific, and 21 generic measures. Of these studies, 47 were cross‐cultural adaptations, 116 single arm, 100 were cross‐sectional, 18 longitudinal and six randomized placebo controlled. DLQI was used for 14 known group, and correlation for 10 construct, 101 convergent, 10 concurrent, 10 divergent/discriminant and three criterion validity tests using Mann–Whitney (2), Spearman's (80), Pearson's correlation (26) and Student's t‐test (1). The DLQI was used in responsiveness analysis in 13 studies.Conclusions: This review identified widespread use of the DLQI in validation of other dermatology PRO/QoL measures and confirmed the central role that the DLQI plays as a benchmark in instrument development and validation across dermatology and beyond. The use of the DLQI by so many developers of other instruments has provided a common standard for comparability.